Literature DB >> 27056325

Regulatory T Cell Modulation by CBP/EP300 Bromodomain Inhibition.

Srimoyee Ghosh1, Alexander Taylor1, Melissa Chin1, Hon-Ren Huang1, Andrew R Conery1, Jennifer A Mertz1, Andres Salmeron1, Pranal J Dakle1, Deanna Mele1, Alexandre Cote1, Hari Jayaram1, Jeremy W Setser1, Florence Poy1, Georgia Hatzivassiliou2, Denise DeAlmeida-Nagata2, Peter Sandy1, Charlie Hatton1, F Anthony Romero2, Eugene Chiang1, Thornik Reimer2, Terry Crawford2, Eneida Pardo1, Venita G Watson1, Vickie Tsui2, Andrea G Cochran2, Laura Zawadzke1, Jean-Christophe Harmange1, James E Audia1, Barbara M Bryant1, Richard T Cummings1, Steven R Magnuson2, Jane L Grogan2, Steve F Bellon1, Brian K Albrecht1, Robert J Sims3, Jose M Lora4.   

Abstract

Covalent modification of histones is a fundamental mechanism of regulated gene expression in eukaryotes, and interpretation of histone modifications is an essential feature of epigenetic control. Bromodomains are specialized binding modules that interact with acetylated histones, linking chromatin recognition to gene transcription. Because of their ability to function in a domain-specific fashion, selective disruption of bromodomain:acetylated histone interactions with chemical probes serves as a powerful means for understanding biological processes regulated by these chromatin adaptors. Here we describe the discovery and characterization of potent and selective small molecule inhibitors for the bromodomains of CREBBP/EP300 that engage their target in cellular assays. We use these tools to demonstrate a critical role for CREBBP/EP300 bromodomains in regulatory T cell biology. Because regulatory T cell recruitment to tumors is a major mechanism of immune evasion by cancer cells, our data highlight the importance of CREBBP/EP300 bromodomain inhibition as a novel, small molecule-based approach for cancer immunotherapy.
© 2016 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Treg, CBP, EP300, bromodomain, histone; acetylation; cellular immune response; chemical biology; chromatin regulation; forkhead box P3 (FOXP3)

Mesh:

Substances:

Year:  2016        PMID: 27056325      PMCID: PMC4933219          DOI: 10.1074/jbc.M115.708560

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  45 in total

Review 1.  CBP/p300 in cell growth, transformation, and development.

Authors:  R H Goodman; S Smolik
Journal:  Genes Dev       Date:  2000-07-01       Impact factor: 11.361

2.  Interplay of bromodomain and histone acetylation in the regulation of p300-dependent genes.

Authors:  Jihong Chen; Feras M Ghazawi; Qiao Li
Journal:  Epigenetics       Date:  2010-08-16       Impact factor: 4.528

Review 3.  Epigenetic modifications and human disease.

Authors:  Anna Portela; Manel Esteller
Journal:  Nat Biotechnol       Date:  2010-10       Impact factor: 54.908

Review 4.  T(H)17 cells in tumour immunity and immunotherapy.

Authors:  Weiping Zou; Nicholas P Restifo
Journal:  Nat Rev Immunol       Date:  2010-04       Impact factor: 53.106

5.  CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.

Authors:  Koji Kono; Hiromichi Kawaida; Akihiro Takahashi; Hidemitsu Sugai; Kosaku Mimura; Naoto Miyagawa; Hideo Omata; Hideki Fujii
Journal:  Cancer Immunol Immunother       Date:  2005-11-23       Impact factor: 6.968

Review 6.  Functions of site-specific histone acetylation and deacetylation.

Authors:  Mona D Shahbazian; Michael Grunstein
Journal:  Annu Rev Biochem       Date:  2007       Impact factor: 23.643

Review 7.  Regulatory T cells in cancer immunotherapy.

Authors:  Hiroyoshi Nishikawa; Shimon Sakaguchi
Journal:  Curr Opin Immunol       Date:  2014-01-14       Impact factor: 7.486

Review 8.  Tregs and rethinking cancer immunotherapy.

Authors:  Tyler J Curiel
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

9.  Dual kinase-bromodomain inhibitors for rationally designed polypharmacology.

Authors:  Pietro Ciceri; Susanne Müller; Alison O'Mahony; Oleg Fedorov; Panagis Filippakopoulos; Jeremy P Hunt; Elisabeth A Lasater; Gabriel Pallares; Sarah Picaud; Christopher Wells; Sarah Martin; Lisa M Wodicka; Neil P Shah; Daniel K Treiber; Stefan Knapp
Journal:  Nat Chem Biol       Date:  2014-03-02       Impact factor: 15.040

10.  CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses.

Authors:  Ariane Hammitzsch; Cynthia Tallant; Oleg Fedorov; Alison O'Mahony; Paul E Brennan; Duncan A Hay; Fernando O Martinez; M Hussein Al-Mossawi; Jelle de Wit; Matteo Vecellio; Christopher Wells; Paul Wordsworth; Susanne Müller; Stefan Knapp; Paul Bowness
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-10       Impact factor: 11.205

View more
  24 in total

1.  GNE-886: A Potent and Selective Inhibitor of the Cat Eye Syndrome Chromosome Region Candidate 2 Bromodomain (CECR2).

Authors:  Terry D Crawford; James E Audia; Steve Bellon; Daniel J Burdick; Archana Bommi-Reddy; Alexandre Côté; Richard T Cummings; Martin Duplessis; E Megan Flynn; Michael Hewitt; Hon-Ren Huang; Hariharan Jayaram; Ying Jiang; Shivangi Joshi; James R Kiefer; Jeremy Murray; Christopher G Nasveschuk; Arianne Neiss; Eneida Pardo; F Anthony Romero; Peter Sandy; Robert J Sims; Yong Tang; Alexander M Taylor; Vickie Tsui; Jian Wang; Shumei Wang; Yongyun Wang; Zhaowu Xu; Laura Zawadzke; Xiaoqin Zhu; Brian K Albrecht; Steven R Magnuson; Andrea G Cochran
Journal:  ACS Med Chem Lett       Date:  2017-06-01       Impact factor: 4.345

Review 2.  The Next Generation of Immunotherapy for Cancer: Small Molecules Could Make Big Waves.

Authors:  William G Kerr; John D Chisholm
Journal:  J Immunol       Date:  2019-01-01       Impact factor: 5.422

Review 3.  The ZZ domain as a new epigenetic reader and a degradation signal sensor.

Authors:  Yi Zhang; Wenyi Mi; Yongming Xue; Xiaobing Shi; Tatiana G Kutateladze
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-01-28       Impact factor: 8.250

Review 4.  Treg programming and therapeutic reprogramming in cancer.

Authors:  Mariela A Moreno Ayala; Zehui Li; Michel DuPage
Journal:  Immunology       Date:  2019-04-29       Impact factor: 7.397

Review 5.  Targeting the epigenetic regulation of antitumour immunity.

Authors:  Simon J Hogg; Paul A Beavis; Mark A Dawson; Ricky W Johnstone
Journal:  Nat Rev Drug Discov       Date:  2020-09-14       Impact factor: 84.694

6.  Modulation of p300/CBP Acetylation of Nucleosomes by Bromodomain Ligand I-CBP112.

Authors:  Beth E Zucconi; Birgit Luef; Wei Xu; Ryan A Henry; Ilana M Nodelman; Gregory D Bowman; Andrew J Andrews; Philip A Cole
Journal:  Biochemistry       Date:  2016-07-01       Impact factor: 3.162

7.  Y08197 is a novel and selective CBP/EP300 bromodomain inhibitor for the treatment of prostate cancer.

Authors:  Ling-Jiao Zou; Qiu-Ping Xiang; Xiao-Qian Xue; Cheng Zhang; Chen-Chang Li; Chao Wang; Qiu Li; Rui Wang; Shuang Wu; Yu-Lai Zhou; Yan Zhang; Yong Xu
Journal:  Acta Pharmacol Sin       Date:  2019-05-16       Impact factor: 6.150

8.  Development of Dimethylisoxazole-Attached Imidazo[1,2-a]pyridines as Potent and Selective CBP/P300 Inhibitors.

Authors:  Alex Muthengi; Virangika K Wimalasena; Hailemichael O Yosief; Melissa J Bikowitz; Logan H Sigua; Tingjian Wang; Deyao Li; Zied Gaieb; Gagan Dhawan; Shuai Liu; Jon Erickson; Rommie E Amaro; Ernst Schönbrunn; Jun Qi; Wei Zhang
Journal:  J Med Chem       Date:  2021-04-19       Impact factor: 7.446

9.  Polyamine metabolism is a central determinant of helper T cell lineage fidelity.

Authors:  Daniel J Puleston; Francesc Baixauli; David E Sanin; Joy Edwards-Hicks; Matteo Villa; Agnieszka M Kabat; Marcin M Kamiński; Michal Stanckzak; Hauke J Weiss; Katarzyna M Grzes; Klara Piletic; Cameron S Field; Mauro Corrado; Fabian Haessler; Chao Wang; Yaarub Musa; Lena Schimmelpfennig; Lea Flachsmann; Gerhard Mittler; Nir Yosef; Vijay K Kuchroo; Joerg M Buescher; Stefan Balabanov; Edward J Pearce; Douglas R Green; Erika L Pearce
Journal:  Cell       Date:  2021-07-02       Impact factor: 66.850

Review 10.  Prostaglandin I2 and T Regulatory Cell Function: Broader Impacts.

Authors:  Allison E Norlander; R Stokes Peebles
Journal:  DNA Cell Biol       Date:  2021-07-15       Impact factor: 3.550

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.